Puma Biotechnology, Inc. PBYI
At closeNov 4, 2026, 7:00 AM EST
Pre-market · Nov 4, 7:00 AM ET
- YTD
- +71.76%
- 1 year
- +102.78%
- Market cap
- 527.56M
- Revenue (ttm)
- 243.57M
- Profit margin
- 9.54%
- EPS (ttm)
- 0.51
- Shares out
- 49.09M
- P/E ratio
- 20.04
- Forward P/E
- 11.71
- YTD return
- +71.76%
- 1-year return
- +102.78%
- Volume
- 406.50K
- Avg volume
- 336.27K
- Open
- 10.23
- Previous close
- 10.18
- Day's range
- 10.08 – 10.42
- 52-week range
- 4.58 – 11.50
- Beta
- 1.08
- Price target
- 4.33 (-57.6%)
2Y +7.27 (+246.44%)
Key statistics
- Enterprise value
- 124.64M
- PEG ratio
- 0.00
- Price / sales
- 0.57
- Price / book
- 1.94
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 43.50%
- Free cash flow
- 32.70M
- Total cash
- 96.72M
- Total debt
- 86.37M
- Return on equity
- 42.32%
- Short % of float
- 6.74%
- 50-day average
- 2.94
- 200-day average
- 3.58
Analyst view
- Target (low)
- 2.00
- Target (mean)
- 4.33
- Target (high)
- 7.00
- Strong buy1
- Buy0
- Hold1
- Sell0
- Strong sell1
Next earnings
Consensus EPS estimate 0.14.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.35 | 0.45 | +0.10 | +28.57% |
| Aug 1, 2024 | Jun 1, 2024 | -0.10 | -0.05 | +0.05 | +50.00% |
| May 2, 2024 | Mar 1, 2024 | -0.16 | -0.05 | +0.11 | +68.75% |
| Feb 29, 2024 | Dec 1, 2023 | 0.37 | 0.31 | -0.06 | -16.22% |
| Nov 2, 2023 | Sep 1, 2023 | 0.15 | 0.17 | +0.02 | +13.33% |
| Aug 3, 2023 | Jun 1, 2023 | 0.07 | 0.10 | +0.03 | +42.86% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- pumabiotechnology.com
News
Puma Biotechnology Reports Q2 2026 Results: Full Earnings Call Transcript 
Puma Biotechnology Initiates ALISertib In CAncer Phase II Trial Of Alisertib In Combination With Paclitaxel For Treatment Of Patients With Advanced Small Cell Lung Cancer 
TD Cowen Maintains Hold on Puma Biotechnology, Raises Price Target to $6 
Puma Biotechnology Sees Q3 Sales $56.000M-$59.000M vs $60.500M Est - Puma Biotechnology Raises FY2026 Sales Guidance from $222.000M-$229.000M to $224.000M-$231.000M vs $222.000M Est
Puma Biotechnology Q2 Adj. EPS $0.19 Beats $0.04 Estimate, Sales $53.600M Beat $53.000M Estimate 
12 Health Care Stocks Moving In Tuesday's After-Market Session 
Puma Biotechnology Sees Q2 Sales $52.000M-$55.000M vs $52.000M Est - Puma Biotechnology Raises FY2026 Sales Guidance from $214.000M-$221.000M to $222.000M-$229.000M vs $218.000M Est
Puma Biotechnology Q1 Adj. EPS $(0.04) Beats $(0.13) Estimate, Sales $44.800M Beat $42.000M Estimate
Your note
Sign in to keep a note on PBYI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AUERBACH ALAN H | Chief Executive Officer | Sale | Jul 16, 2024 | 7,063,520 |
| DORVAL ALLISON | Director | Stock Award(Grant) | Jun 17, 2024 | 60,000 |
| HUNT DOUGLAS M | Officer | Sale | Jul 16, 2024 | 133,227 |
| LUDWIG JEFFREY JEROME | Officer | Sale | Jul 16, 2024 | 118,388 |
| MILLER MICHAEL PATRICK | Director | Sale | Aug 11, 2024 | 47,000 |
| MOYES JAY M | Director | Stock Award(Grant) | Jun 17, 2024 | 48,322 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.80% | 3,827,223 | 10.75M | Sep 29, 2024 |
| Vanguard Group Inc | 7.41% | 3,636,191 | 10.22M | Sep 29, 2024 |
| Frazier Life Sciences Management, L.P. | 6.24% | 3,062,558 | 8.61M | Sep 29, 2024 |
| Millennium Management Llc | 5.87% | 2,880,888 | 8.10M | Sep 29, 2024 |
| Acadian Asset Management. LLC | 4.01% | 1,968,999 | 5.53M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 3.61% | 1,772,413 | 4.98M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.59% | 1,271,564 | 3.57M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.20% | 1,080,781 | 3.04M | Oct 30, 2024 |
| Vanguard Explorer Fund, Inc. | 1.58% | 777,390 | 2.18M | Jul 30, 2024 |
| Avantis U.S. Small Cap Value ETF | 1.46% | 718,454 | 2.02M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.19% | 585,850 | 1.65M | Sep 29, 2024 |
| Vanguard Strategic Equity Fund | 1.10% | 540,434 | 1.52M | Sep 29, 2024 |